U.S. Government Spending on Weight-Loss Drugs Would Raise Deficit, CBO Says
By Dominic Chopping
The U.S. Congressional Budget Office said in a presentation Wednesday that government spending on weight-loss drugs would raise the U.S. deficit over the next 10 years.
The CBO--which provides independent analysis of economic and budgetary issues--was presenting its budgetary analysis on a policy that could allow Medicare coverage of medications to treat obesity.
Medicare currently covers obesity treatments that include bariatric surgery, behavioral counseling, obesity screening and intensive behavioral therapy, but it doesn't cover new anti-obesity medications such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound.
A new bill proposed to Congress seeks to allow Medicare to cover these medications and the CBO expects considerable demand for the drugs should the Medicare coverage be expanded.
"CBO expects that at their current prices, anti-obesity medications would cost the federal government more than it would save from reducing health care spending - which would lead to an overall increase in the deficit over the next 10 years," it said in the presentation.
Depending on the future prices of these drugs and their longer-term effects on the use of other health care products and services, the budgetary effect could change in later decades, it added.
The current price for a four-week supply of GLP-1 weight-loss drugs ranges from around $1,100 to $1,300 and the CBO said that if the drugs were covered by Medicare some of the cost would be paid by the patient while the amount received by the manufacturer would probably be reduced due to discounts.
Novo Nordisk shares fell 2% in afternoon trade in Copenhagen.
Write to Dominic Chopping at dominic.chopping@wsj.com
(END) Dow Jones Newswires
March 21, 2024 09:11 ET (13:11 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
5 Stocks to Buy That We Still Like After They’ve Run Up
-
Markets Brief: Stocks Are Starting to Look Cheap Again
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year
-
Snap Earnings: Advertising Growth and Snapchat+ Drive Monetization
-
STMicro Earnings: We Still See an Attractive Margin of Safety Despite a Poor First-Half Forecast
-
Alphabet Shares Surge on Strong Earnings, Dividend Surprise
-
Microsoft Earnings: Firm Beats Forecasts on Strong AI and Cloud Demand
-
PG&E Earnings: Near-Term Regulatory Certainty Supports Industry-Leading Earnings Growth